15 research outputs found
ΠΠΈΠ½Π°ΠΌΠΈΠΊΠ° ΠΌΠΈΠ½Π΅ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΠ»ΠΎΡΠ½ΠΎΡΡΠΈ ΠΊΠΎΡΡΠΈ Π½Π° ΡΠΎΠ½Π΅ 4-Π»Π΅ΡΠ½Π΅ΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠΈΡΡΠΊΡΠΈΠΌΠ°Π±ΠΎΠΌ Ρ ΠΆΠ΅Π½ΡΠΈΠ½ Π² ΠΏΠΎΡΡΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Π΅, ΡΡΡΠ°Π΄Π°ΡΡΠΈΡ ΡΠ΅Π²ΠΌΠ°ΡΠΎΠΈΠ΄Π½ΡΠΌ Π°ΡΡΡΠΈΡΠΎΠΌ
Objective: to estimate the time course of bone mineral density (BMD) changes during 4-year rituximab (RTM) therapy in postmenopausal women with rheumatoid arthritis (RA).Subjects and methods. Seventy-nine postmenopausal women with a valid diagnosis of RA were followed up. According to the basic therapy option, all the patients were allocated into two groups: 1) 44 patients who received combination therapy with RTM and methotrexate (MT); 2) 35 patients who had MT monotherapy. BMD was estimated by dual-energy X-ray absorptiometry using an Excell XR-46 stationary dualenergy X-ray bone densitometer (Norland, USA).Results. There was a statistically significant increase in femoral neck BMD and T score as compared to the baseline values in the RTM group after 3 years of follow-up. The MT monotherapy group showed no statistically significant densitometric changes in the femoral neck. The similar positive BMD changes were observed 4 years following RTM and MT therapy.Conclusion. Following 2 therapy cycles, femoral neck BMD parameters were noted to be stabilized in the patients with RA. After 3 therapy cycles, there was a positive densitometric change that remained by the fourth therapy cycle.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΎΡΠ΅Π½ΠΊΠ° Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΈ ΠΌΠΈΠ½Π΅ΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΠ»ΠΎΡΠ½ΠΎΡΡΠΈ ΠΊΠΎΡΡΠΈ (ΠΠΠ) ΡΠ΅ΠΉΠΊΠΈ Π±Π΅Π΄ΡΠ° Π½Π° ΡΠΎΠ½Π΅ 4-Π»Π΅ΡΠ½Π΅ΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠΈΡΡΠΊΡΠΈΠΌΠ°Π±ΠΎΠΌ (Π Π’Π) Ρ ΠΆΠ΅Π½ΡΠΈΠ½ Π² ΠΏΠΎΡΡΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Π΅, ΡΡΡΠ°Π΄Π°ΡΡΠΈΡ
ΡΠ΅Π²ΠΌΠ°ΡΠΎΠΈΠ΄Π½ΡΠΌ Π°ΡΡΡΠΈΡΠΎΠΌ (Π Π).ΠΠ°ΡΠ΅ΡΠΈΠ°Π» ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠΎΠ΄ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΠ΅ΠΌ Π½Π°Ρ
ΠΎΠ΄ΠΈΠ»ΠΎΡΡ 79 ΠΆΠ΅Π½ΡΠΈΠ½ Π² ΠΏΠΎΡΡΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Π΅ Ρ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΡΠΌ Π΄ΠΈΠ°Π³Π½ΠΎΠ·ΠΎΠΌ Π Π. ΠΡΠ΅ Π±ΠΎΠ»ΡΠ½ΡΠ΅ Π±ΡΠ»ΠΈ ΡΠ°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Ρ Π² Π΄Π²Π΅ Π³ΡΡΠΏΠΏΡ Π² Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ Π²Π°ΡΠΈΠ°Π½ΡΠ° Π±Π°Π·ΠΈΡΠ½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ: 1-Ρ Π³ΡΡΠΏΠΏΠ° (n=44) ΠΏΠΎΠ»ΡΡΠ°Π»Π° ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π Π’Π ΠΈ ΠΌΠ΅ΡΠΎΡΡΠ΅ΠΊΡΠ°ΡΠΎΠΌ (ΠΠ’); 2-Ρ Π³ΡΡΠΏΠΏΠ° (n=35) β ΠΌΠΎΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΠ’. ΠΠΠ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ Π΄Π²ΡΡ
ΡΠ½Π΅ΡΠ³Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ²ΡΠΊΠΎΠΉ Π°Π±ΡΠΎΡΠ±ΡΠΈΠΎΠΌΠ΅ΡΡΠΈΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ½ΠΎΠ³ΠΎ Π΄Π²ΡΡ
ΡΠ½Π΅ΡΠ³Π΅ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ²ΡΠΊΠΎΠ³ΠΎ ΠΊΠΎΡΡΠ½ΠΎΠ³ΠΎ Π΄Π΅Π½ΡΠΈΡΠΎΠΌΠ΅ΡΡΠ° Exceell XR-46 (Norland, Π‘Π¨Π).Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΠΎΠ΅ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΠΠ ΠΈ Π’-ΠΊΡΠΈΡΠ΅ΡΠΈΡ ΡΠ΅ΠΉΠΊΠΈ Π±Π΅Π΄ΡΠ° ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΈΡΡ
ΠΎΠ΄Π½ΡΠΌΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌΠΈ ΡΠ΅ΡΠ΅Π· 3 Π³ΠΎΠ΄Π° Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ Π² Π³ΡΡΠΏΠΏΠ΅ Π±ΠΎΠ»ΡΠ½ΡΡ
, ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΡ
Π Π’Π. Π Π³ΡΡΠΏΠΏΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ, ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΡ
ΠΌΠΎΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΠ’, ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΠΎΠ³ΠΎ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ Π΄Π΅Π½ΡΠΈΡΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΡΠ΅ΠΉΠΊΠΈ Π±Π΅Π΄ΡΠ° Π½Π΅ ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ. ΠΠ½Π°Π»ΠΎΠ³ΠΈΡΠ½Π°Ρ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½Π°Ρ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ° ΠΠΠ Π½Π°Π±Π»ΡΠ΄Π°Π»Π°ΡΡ ΡΠ΅ΡΠ΅Π· 4 Π³ΠΎΠ΄Π° ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π Π’Π ΠΈ ΠΠ’.ΠΡΠ²ΠΎΠ΄Ρ. ΠΠΎΡΠ»Π΅ 2 ΠΊΡΡΡΠΎΠ² ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΎΡΠΌΠ΅ΡΠ΅Π½Π° ΡΡΠ°Π±ΠΈΠ»ΠΈΠ·Π°ΡΠΈΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΠΠΠ ΡΠ΅ΠΉΠΊΠΈ Π±Π΅Π΄ΡΠ° Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Π Π. ΠΠΎΡΠ»Π΅ 3 ΠΊΡΡΡΠΎΠ² Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»Π°ΡΡ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½Π°Ρ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ° Π΄Π΅Π½ΡΠΈΡΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ, ΠΊΠΎΡΠΎΡΠ°Ρ ΡΠΎΡ
ΡΠ°Π½ΡΠ»Π°ΡΡ ΠΈ ΠΊ 4-ΠΌΡ ΠΊΡΡΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ
Time course of bone mineral density changes during 4-year rituximab therapy in postmenopausal women with rheumatoid arthritis
Objective: to estimate the time course of bone mineral density (BMD) changes during 4-year rituximab (RTM) therapy in postmenopausal women with rheumatoid arthritis (RA).Subjects and methods. Seventy-nine postmenopausal women with a valid diagnosis of RA were followed up. According to the basic therapy option, all the patients were allocated into two groups: 1) 44 patients who received combination therapy with RTM and methotrexate (MT); 2) 35 patients who had MT monotherapy. BMD was estimated by dual-energy X-ray absorptiometry using an Excell XR-46 stationary dualenergy X-ray bone densitometer (Norland, USA).Results. There was a statistically significant increase in femoral neck BMD and T score as compared to the baseline values in the RTM group after 3 years of follow-up. The MT monotherapy group showed no statistically significant densitometric changes in the femoral neck. The similar positive BMD changes were observed 4 years following RTM and MT therapy.Conclusion. Following 2 therapy cycles, femoral neck BMD parameters were noted to be stabilized in the patients with RA. After 3 therapy cycles, there was a positive densitometric change that remained by the fourth therapy cycle
Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
Progress in the understanding of many tumors has enabled the development of new therapies, such as those targeted at specific molecules involved in cell growth (targeted therapies) or intended to modulate the immune system (immunotherapy). However, along with the clinical benefit provided by these new treatments, new adverse effects have also appeared. Dermatological toxicities such as papulopustular eruptions, xerosis, and pruritus are common with EGFR inhibitors. Other adverse effects have also been described with PDGFR, BCR-ABL, and MAPK tyrosine kinase inhibitors, antiangiogenic drugs, and inhibitors at immune checkpoints such as CTLA-4 and PD-1/PD-L1. Onset of these adverse effects often causes dose reductions and/or delays in administering the prescribed therapy, which can affect patient survival and quality of life. It is, therefore, important to prevent the occurrence of these adverse effects, or to treat unavoidable ones as soon as possible. This requires cooperation between medical oncologists and dermatologists. This article reviews the various dermatological toxicities associated with targeted therapies and immunotherapies, along with their diagnosis and therapeutic management